Focal facial dermal dysplasia type III
foh-kuhl FAY-shuhl DUR-muhl DIS-plee-zhuh type three
Also known as: Setleis syndrome, Focal facial dermal dysplasia, type III
At a Glance
What is Focal facial dermal dysplasia type III?
Focal facial dermal dysplasia type III, also known as Setleis syndrome, is a rare genetic disorder that primarily affects the skin on the face. It is characterized by distinctive facial features, including bitemporal scar-like lesions and other skin abnormalities. This condition is caused by duplications or triplications in the chromosome region 1p36.22p36.21. Over time, individuals may experience additional dermatological symptoms, but the condition does not typically worsen significantly. Early symptoms include the characteristic facial lesions, while later symptoms may involve other skin changes. Early diagnosis is critical to manage symptoms and provide genetic counseling to affected families. The condition can impact family life due to its genetic nature and potential for inheritance. The prognosis for individuals with this condition is generally good, as it primarily affects the skin without major systemic involvement. Daily life for affected individuals may involve managing skin care and monitoring for any additional symptoms. Despite the cosmetic impact, most individuals lead a normal life span. Genetic counseling is recommended for families to understand inheritance patterns. Support groups and resources can provide additional assistance to affected families.
Medical Definition
Focal facial dermal dysplasia type III is a genetic disorder caused by duplications or triplications in the chromosome region 1p36.22p36.21, leading to characteristic facial skin lesions. Pathologically, it involves dermal dysplasia with bitemporal scar-like lesions and other facial skin abnormalities. Histological findings typically show dermal fibrosis and altered collagen deposition. It is classified under rare genetic dermatological disorders with autosomal dominant inheritance. Epidemiologically, it is extremely rare, with a prevalence of approximately 1 in 1,000,000. The disease course is generally stable, with symptoms present from birth and minimal progression over time.
Focal facial dermal dysplasia type III Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Bitemporal scar-like lesions manifest as symmetrical, atrophic, and scarred areas on the temples. These lesions are caused by abnormal dermal development due to genetic duplications or triplications affecting skin morphogenesis. Over time, the lesions may become more pronounced but typically do not change significantly after childhood. They can affect a patient's self-esteem and social interactions, but cosmetic interventions such as dermabrasion or laser therapy may improve appearance.
Sparse or absent eyelashes are characterized by a reduction or complete lack of eyelashes, particularly on the upper eyelids. This symptom results from disrupted hair follicle development due to genetic anomalies in the affected chromosomal region. The condition is usually present from birth and remains stable throughout life. It can lead to increased eye irritation and vulnerability to foreign particles, but artificial eyelashes or protective eyewear can help manage these issues.
Periorbital wrinkling appears as excessive folds or creases around the eyes, giving a prematurely aged appearance. This occurs due to abnormal skin elasticity and collagen formation linked to the genetic condition. The wrinkling tends to become more noticeable with age but does not typically worsen significantly. It may affect the individual's confidence and social interactions, but cosmetic treatments like fillers or skin-tightening procedures can offer improvement.
Common
Hypoplastic eyebrows are characterized by underdeveloped or sparse eyebrow hair. This results from impaired follicular development due to genetic mutations affecting the skin and hair. The condition is usually evident from early childhood and remains consistent throughout life. It can impact facial expression and aesthetics, but cosmetic solutions such as eyebrow pencils or microblading can enhance appearance.
Nasal tip deformity manifests as an unusual shape or structure of the nasal tip, often broad or flattened. This deformity is caused by abnormal cartilage development influenced by genetic factors. It is typically present at birth and remains unchanged over time. The deformity can affect breathing and appearance, but surgical correction can improve both function and aesthetics.
Thickened skin presents as areas of the skin that are denser and less pliable than normal. This occurs due to excessive collagen deposition and altered dermal structure associated with the genetic condition. The thickening may become more apparent with age but generally stabilizes after adolescence. It can lead to discomfort and reduced skin flexibility, but moisturizing and topical treatments can alleviate symptoms.
Less Common
Ectropion is the outward turning of the eyelid margin, exposing the inner eyelid surface. This condition arises from weakened or malformed eyelid tissues due to genetic abnormalities. It may progress slowly, leading to increased eye irritation and dryness. Surgical intervention can correct the eyelid position and alleviate associated symptoms.
Lip pits are small depressions or indentations on the lip surface, often located at the corners of the mouth. They result from incomplete fusion of embryonic facial structures influenced by genetic factors. Lip pits are typically present from birth and do not change significantly over time. They are usually asymptomatic but can be surgically excised if desired for cosmetic reasons.
What Causes Focal facial dermal dysplasia type III?
Focal facial dermal dysplasia type III, also known as Setleis syndrome, is primarily caused by duplications or triplications at the chromosomal region 1p36.22p36.21. This region includes several genes, but the exact causative gene(s) remain to be fully elucidated. The encoded proteins from this region are believed to play roles in skin development and facial morphogenesis. Mutations such as duplications or triplications can lead to altered gene dosage, disrupting normal protein expression levels. This disruption can cause aberrant signaling pathways within the cell, leading to impaired cellular functions. Organelle dysfunction, particularly in the endoplasmic reticulum and Golgi apparatus, may result from these molecular changes. The downstream effects include altered extracellular matrix composition and impaired cell-cell adhesion in dermal tissues. Neuroinflammation and immune responses may be triggered as a secondary effect of cellular stress and tissue damage. Degeneration of structures such as white matter has not been directly linked to this condition, but skin and facial tissue abnormalities are prominent. Symptoms appear in a specific pattern due to the localized expression of affected genes in facial tissues. Variability in disease severity among patients may be attributed to differences in the extent of chromosomal duplication or triplication and genetic background. Environmental factors and epigenetic modifications might also play a role in phenotypic variability. Further research is needed to identify the precise gene(s) involved and their specific contributions to the phenotype. Understanding the molecular mechanisms will aid in the development of targeted therapies. Genetic counseling is recommended for affected families due to the hereditary nature of the chromosomal aberrations.
How is Focal facial dermal dysplasia type III Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in early childhood when characteristic facial features become apparent, often prompting evaluation by a pediatrician or geneticist.
Clinicians look for distinctive facial features such as bitemporal scars and a flattened nasal bridge. A detailed family history is important to identify any hereditary patterns. Physical examination focuses on facial morphology and skin texture. This step helps determine the need for further genetic testing.
MRI or CT scans are used to assess craniofacial structures. Abnormalities such as soft tissue underdevelopment may be visible. Imaging findings support the diagnosis by correlating with clinical features. Differential diagnoses like craniosynostosis are excluded based on imaging results.
Routine blood tests are not typically diagnostic but may rule out other conditions. Biomarkers specific to skin or connective tissue disorders are not usually present. Abnormal results may include atypical skin biopsy findings. These results guide the decision to pursue genetic testing.
Genes in the 1p36.22p36.21 region are sequenced to identify duplications or triplications. Mutations such as copy number variations are found. Positive results confirm the diagnosis of focal facial dermal dysplasia type III. Genetic findings inform family counseling regarding inheritance patterns.
Focal facial dermal dysplasia type III Treatment Options
Topical retinoids are used to improve skin texture by promoting cell turnover. They work by modulating gene expression in skin cells. Specific drugs include tretinoin and adapalene. Clinical evidence shows modest improvement in skin appearance. Side effects may include skin irritation and photosensitivity.
Techniques focus on strengthening facial muscles to improve expression. The goal is to enhance facial symmetry and function. Sessions are typically conducted twice a week for several months. Outcomes are measured by improved muscle tone and facial movement. Long-term benefits include better facial coordination.
Surgery is indicated for significant facial scarring impacting function or appearance. The procedure involves excising scar tissue and reconstructing skin. Benefits include improved aesthetic appearance and reduced scar visibility. Risks include infection and scarring recurrence. Post-operative care involves wound management and follow-up evaluations.
The care team includes dermatologists, geneticists, and psychologists. Interventions focus on managing symptoms and providing psychosocial support. Strategies include counseling and support groups for patients and families. Education is provided on condition management and genetic implications. Long-term monitoring involves regular follow-ups to assess treatment efficacy.
When to See a Doctor for Focal facial dermal dysplasia type III
- Severe facial deformities — may indicate a significant underlying genetic anomaly requiring immediate evaluation.
- Sudden vision loss — could suggest complications affecting the optic nerve or brain, necessitating urgent care.
- Difficulty breathing — may be due to structural facial abnormalities impacting airways, requiring emergency intervention.
- Progressive facial changes — could indicate worsening of the condition, and a specialist should evaluate the progression.
- Delayed developmental milestones — may suggest associated neurological issues, and a pediatrician should assess for intervention.
- Persistent skin lesions — could be indicative of complications or infections, and dermatological consultation is advised.
- Mild facial asymmetry — monitor for any changes or progression, and consult a doctor if it worsens.
- Occasional skin irritation — keep track of triggers and manage with recommended skincare, consult if persistent.
Focal facial dermal dysplasia type III — Frequently Asked Questions
Is this condition hereditary?
Focal facial dermal dysplasia type III is often inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to children if one parent is affected. However, de novo mutations can also occur, meaning the condition can appear without a family history. Carriers may not show symptoms but can still pass the mutation to offspring. Genetic counseling is recommended for affected families to understand their risks and options.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the severity and associated complications. Early diagnosis and management of symptoms can improve outcomes and quality of life. Mortality is rarely directly caused by the condition itself but may result from complications like infections. Treatment and supportive care can significantly enhance survival and daily functioning. Realistic expectations include managing symptoms and adapting to lifestyle changes.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, genetic testing, and family history assessment. The time from first symptoms to diagnosis can vary, often taking several months to years due to the rarity of the condition. Specialists such as geneticists, dermatologists, and pediatricians are usually consulted. Delayed diagnosis is common due to symptom overlap with other conditions. Genetic testing confirming the specific chromosomal duplication or triplication ultimately confirms the diagnosis.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and other novel treatments for genetic conditions like focal facial dermal dysplasia type III. Clinical trials may be available and can be found on ClinicalTrials.gov by searching for related terms. Patients should discuss potential trials and new treatments with their doctors to understand eligibility and potential benefits. It's important to ask about the risks and expected outcomes of participating in a trial. New treatments may still be several years away from widespread availability.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care depending on the severity of facial abnormalities. Educational challenges may arise due to associated developmental delays or learning disabilities. Social and emotional challenges are common due to visible differences and potential stigmatization. The family may experience a significant burden in terms of care and support needs. Supports such as therapy, educational accommodations, and community resources can greatly aid in adaptation.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Chromosome 1p36.22p36.21 duplications/triplication causes Setleis syndrome (focal facial dermal dysplasia type III).
Weaver DD, Norby AR, Rosenfeld JA et al. · Am J Med Genet A · 2015 · PMID: 25728400
- 2.De novo triplication at 1p36.23p36.22 further refines the dosage sensitive region of overlap in Setleis syndrome (focal facial dermal dysplasia type III).
Oh RY, Chun K, Kowalski PE et al. · Am J Med Genet A · 2023 · PMID: 36942595
- 3.Setleis syndrome due to inheritance of the 1p36.22p36.21 duplication: evidence for lack of penetrance.
Lee BH, Kasparis C, Chen B et al. · J Hum Genet · 2015 · PMID: 26311541
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-11